Regencell Bioscience Holdings, a revenue-negative early-stage bioscience business situated in Hong Kong, is the most recent speculative foreign stock to see an unexpected spike in trading demand.
Regencell’s stock more than tripled on Monday, rising more than 280% by the end of the day.
The company claims to be developing traditional Chinese herb remedies to treat autism and attention deficit hyperactivity disorder in children.
Monday was the first day of a 38-for-1 split that was announced on June 2.
Source (CNBC)
